Repligen Corporation
RGEN
Classificação em ações
#1866
Repligen Corporation specializes in the creation and distribution of advanced... Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Preço da ação
$179.36
Última sincronização: 2026-10-20
Valor de mercado
$11.39B
Variação (1 dia)
1.66%
Variação (1 ano)
14.42%
País
US
Negociar Repligen Corporation (RGEN)
Categoria
Healthcare
Rácio P/E de Repligen Corporation (RGEN)
Rácio P/E em October 2026 TTM: 240.81
De acordo com os últimos relatórios financeiros e o preço das ações da Repligen Corporation, o rácio P/E atual (TTM) é 240.81. No final de 2023, a empresa tinha um P/E de 281.45.
Histórico do rácio P/E da Repligen Corporation de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 240.81 | -176.31% |
| 2024 | -315.57 | -212.13% |
| 2023 | 281.45 | 457.38% |
| 2022 | 50.49 | -55.54% |
| 2021 | 113.57 | -32.42% |
| 2020 | 168.06 | -19.53% |
| 2019 | 208.85 | 50.35% |
| 2018 | 138.91 | 183.93% |
| 2017 | 48.92 | -44.77% |
| 2016 | 88.58 | -11.01% |
| 2015 | 99.54 | 26.39% |
| 2014 | 78.76 | 193.43% |
| 2013 | 26.84 | 95.70% |
| 2012 | 13.71 | -100.52% |
| 2011 | -2.65K | 8,512.40% |
| 2010 | -30.72 | -219.05% |
| 2009 | 25.81 | 544.33% |
| 2008 | 4.01 | -103.71% |
| 2007 | -107.95 | -167.49% |
| 2006 | 159.95 | -1,033.81% |
| 2005 | -17.13 | 81.87% |
| 2004 | -9.42 | -65.88% |
| 2003 | -27.60 | 18.19% |
| 2002 | -23.35 | 61.51% |
| 2001 | -14.46 | -73.38% |
| 2000 | -54.32 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 47.48 | -80.28% |
US
|
|
| 27.43 | -88.61% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -76.37% |
US
|
|
| - | - |
CH
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.